SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$12.85
 
Market cap
$1.40B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 24, 2020
Market Cap$1.40B-16.2%
Revenue (ttm)$701.94M+738.8%
Net Income$294.88M+220.5%
EPS$2.31+177.8%
Shares Out109.25M
PE Ratio5.12
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Beta1.80
Analystsn/a
Price Target$28.00(+117.98%)
Earnings DateJan 27, 2027

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Address
1600 Sierra Point Parkway, Brisbane, CA, 94005, US
Market Cap
1.40 billion
Employees
317
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.54M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy1 Hold0 SellAvg target $30.50 (+137.4%)

7 firms rating NRIX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From NRIX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.51%
5 Days
-16.99%
1 Month
-49.63%
6 Months
-26.57%
1 Year
-16.18%

$NRIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in NRIX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NRIX's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NRIX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

NRIX Revenue by Segment

$22.13MTotal
Bexobrutideg (NX-5948)$19.98M90.27%
NX-1607$1.47M6.66%
Zelebrudomide (NX-2127)$681.00K3.08%

As of: Q3 2026 (Aug 31, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New NRIX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NRIX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in NRIX

VTIVanguard Morningstar Total Stock Market ETF$69.78M
ARKGARK Genomic Revolution ETF$36.09M
IWMiShares Russell 2000 ETF$34.17M
XBIState Street SPDR S&P Biotech ETF$30.56M
VXFVanguard Extended Market ETF$29.77M
VTWOVanguard Russell 2000 ETF$15.11M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from NRIX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
60

News check: Nurix made two positive announcements: CMO appointment and investor conference participation, indicating organizational strength and investor engagement.

Recent Insider Activity

Buys
0
Sells
13
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-37.0 since Aug 21
0255075100Aug 21 — Insider Score 37.0Aug 22 — Insider Score 38.0Aug 23 — Insider Score 38.0Aug 24 — Insider Score 38.0Aug 25 — Insider Score 38.0Aug 26 — Insider Score 38.0Aug 27 — Insider Score 38.0Aug 28 — Insider Score 38.0Aug 29 — Insider Score 38.0Aug 30 — Insider Score 38.0Aug 31 — Insider Score 38.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 23.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ADDSHedgeye Index Adds ETF2.33%
ARKGARK Genomic Revolution ETF2.19%
HEALGlobal X HealthTech ETF1.27%
PTHInvesco Dorsey Wright Healthcare Momentum ETF0.86%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.80%
BBCVirtus Biotech Clinical Trials ETF0.71%
WDNAWisdomTree BioRevolution Fund0.69%
TDNAT. Rowe Price Biotech ETF0.68%
AESGHarbor AlphaEdge Small Cap Growth ETF0.63%
AESBHarbor AlphaEdge Small Cap Core ETF0.53%
AESLHarbor AlphaEdge Small Cap Value ETF0.48%
SEISSEI Exchange Traded Funds - SEI Select Small Cap ETF0.39%

Weight is the stock’s share of each fund’s holdings.